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The impact of CD27 costimulation on human Tlymphocyte effector function and memory formation has been limited to
evaluations using in vitro cell culture systems and observations from the clinic. We therefore investigated whether CD27
signaling augments antigen redirected human T-cell survival, expansion and function in vitro and in vivo.
CD27 (TNFRSF7) is a transmembrane
receptor expressed on subsets of human
CD8
+ and CD4
+ T-cells, NKT cells, NK
cell subsets and hematopoietic progenitors
and induced in FOXP3
+ CD4 T-cells and
B cell subsets. CD27 commonly serves
as a T-cell differentiation antigen but its
role in functional T-cell memory forma-
tion is still emerging. CD27 is dispensable
for immune development in mice;
however, T-cell memory responses are
impaired in formation, kinetics of response
and cell number.
1 Normal cell division
but low [H
3]thymidine incorporation by
CD27
2/2 T cells following CD3 stimu-
lation in vitro has implicated CD27 as an
enabler of activated T-cell survival.
1
The role of CD27 signaling in human
T-cell survival and memory formation is
more difficult to assess. CD27 facilitates
mitogen or CD3-stimulated human T-cell
proliferation in vitro,
2 but its role in vivo is
unclear. We first observed in a trial of
adoptive T-cell therapy that the absolute
number of transferred human CD27
+
tumor antigen-specific T-cells that persist
long-term in patients responding to ther-
apy is remarkably stable.
3 Ultimately,
the CD27
+ subset comprised the entire
antigen-specific memory pool as CD27
-
T-cell numbers contracted, implicating
a survival advantage.
3 T cell persistence
is correlated with clinical responses to
adoptive immunotherapy, emphasizing
the importance of these observations.
4
Clinical response is also associated with
the transfer of high numbers of CD27
+
T cells.
5 Together, these results imply
that CD27 identifies a human antigen-
experienced T-cell precursor to the emer-
gent memory population. Here, CD27
may either actively provide costimulatory
signals that improve human T-cell survival
and anti-tumor activity in vivo, or alter-
natively serve as a functionally dispensable
marker of the evolving memory pool.
We recently investigated CD27 costi-
mulatory function in primary human
T-cells utilizing chimeric antigen receptor
(CAR) technology.
6 CARs couple antigen-
specific targeting of an extracellular
antibody scFv with intracellular T-cell
signaling domains for the generation of
antigen-redirected T cells for therapy.
T cells were engineered to express either
second generation CARs, which incorpo-
rate a TCR CD3f intracellular domain
(ICD) in tandem with the CD27 ICD,
containing the TRAF-binding domain
essential for CD27 function, or a first
generation CAR containing the CD3f
ICD alone. Various costimulatory
domains have been tested in CAR con-
structs including CD28, 41BB, ICOS
and OX40. These second generation
CARs impart augmented functions to
T-cells relative to first generation CARs,
making this a suitable model system
for evaluating costimulatory function in
human T-cells.
CD27 bolstered human CAR T-cell
activity in vitro resulting in greater Th-1
cytokine secretion (IFNc, TNFa and
IL-2) and cytotoxicity when co-cultured
with antigen-expressing cancer cells in
vitro, compared with CAR T-cells with
CD3f alone. CD27 signaling actively
reinforced a Th-1 profile in CD4
+ and
CD8
+ CAR T-cells since levels of
secreted Th-2 cytokines, IL-4 and IL-10,
were uniformly lower in CAR T-cells
with CD27-CD3f ICDs, compared with
CD3f alone. Antigen-stimulated CAR
T-cells underwent equal cell division with
or without the CD27 ICD, but CD27
costimulation fostered upregulated anti-
apoptotic Bcl-XL protein expression and
resistance to antigen-induced apoptosis,
leading to increased numerical expansion.
These effects were antigen-dependent,
precluding constitutive CD27 activity.
This has an important implication on the
interpretation of in vitro functional assay
results, particularly that the observed
increase in net effector function by
CD27-costimulated CAR cells in co-
culture may reflect augmented cell sur-
vival, and not increased function at
cellular level.
Given the role of CD27 on T-cell
survival in mice, the impact of CD27
costimulation on human CAR T-cell
survival was evaluated in vivo using a
human ovarian cancer xenograft model.
CD4
+ and CD8
+ T cells expressing the
CD27-costimulated CAR demonstrated
heightened antigen-dependent persistence
after infusion. Interestingly, incorporation
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of a CD28 ICD into CAR T-cells was
incapable of achieving such levels of
persistence, although incorporation of the
ICD from 41BB, another TNF-R family
member, did. Persistence under CD28
costimulation was identical to that
achieved with CD3z alone, indicating
that CD28 does not support human
T-cell survival in vivo, consistent with
clinical observations.
3 Improved T-cell
persistence by CD27 containing CARs
was associated with improved regression of
established cancer. Thus, CD27 costimu-
lation enhances the survival and antitumor
activity of human CAR-expressing T cells
in vivo. A schematic summary of these
results is provided (Fig.1).
Still, treatment with CAR T cells
containing a CD27, CD28 or 41BB
ICD yielded similar tumor responses; all
superior to a first generation CAR. With
discordance in T-cell survival in vivo
among these groups, how might this then
be explained? In virus-infected mice,
CD27 promotes activated CD8
+ T-cell
survival facilitating increased T-cell accu-
mulation independently of CD28,
7 which
affects T-cell activity. We hypothesize that
increased survival and accumulation of
CD27 CAR T cells facilitates a quantita-
tively increased response, while greater
activity but poor survival by CD28 CAR
T cells enables similar tumor responses.
Formal testing of this hypothesis is under
investigation.
Clinical application of CD27 ICD-
containing CAR T cells is yet untested.
Our data, coupled with prior clinical
observations,
3,5 suggest that greater
T-cell persistence promoted by CD27
costimulation may improve clinical effi-
cacy of adoptive immunotherapy. Mecha-
nisms accounting for CD27-mediated
human T-cell survival in vivo may include
upregulation of anti-apoptotic molecules,
instructed CD4 help
8 and autocrine IL-2
production by CD8
+ T cells in vivo.
9
Identification of CD27 deficiency in
individuals with persistent EBV viremia
10
suggests that CD27 is dispensable for
T-cell development and priming, but
required for antigen recall responses,
particularly IL-2 production by CD8
+
T cells, akin to CD27
2/2 mouse results.
9
With the availability of gene transfer
technology, agonistic antibodies and
clinical-grade enrichment devices, the
impact of CD27 costimulation on T-cell
activity and survival is rapidly approaching
clinical application.
Figure1. A schematic representation of the impact of CD27 costimulatory function on human T-cell survival, expansion and activity in vitro and in vivo.
Primary T cells redirected against a tumor associated antigen via chimeric antigen receptor containing the CD27 intracellular signaling domain mediate
improved antitumor activity in vivo upon transfer, which is associated with improved T-cell persistence.
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